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Clinical Implications This subgroup analysis of COMPACT trial data suggests
that patients with hereditary angioedema using
intravenous human C1-inhibitor as routine prophylaxis
can derive a clinically meaningful benefit when switched
to prophylaxis with subcutaneous human C1-inhibitor,
observable as a further reduction in hereditary
angioedema attacks.TO THE EDITOR:
Hereditary angioedema (HAE) is a rare, debilitating, and
potentially life-threatening condition typically resulting from
deficiency (type 1 HAE) or dysfunction (type 2 HAE) of the
C1-inhibitor (C1-INH) protein.1 International HAE manage-
ment guidelines recommend that all patients be evaluated for
long-term (routine) prophylaxis and that human, plasma-derived
C1-INH has been cited as a first-line option.2 Intravenous (IV)
human C1-INH (C1-INH[IV]; Cinryze, Shire), Food and Drug
Administration (FDA) approved in 2008,3 was the first C1-INH
product specifically indicated for routine prophylaxis and repre-
sented a major advancement in HAE management. However, its
use entails an ongoing need for venous access and possibility of
related complications. In addition, breakthrough attacks are
common at the initial FDA-approved dose, and only a minority
of patients are completely attack free.4-6
A volume-reduced formulation of human C1-INH for sub-
cutaneous (SC) administration (C1-INH[SC]; HAEGARDA,
CSL Behring)7 was FDA approved in June 2017 for routine
prevention of HAE attacks. Twice-weekly administration of C1-
INH(SC) significantly reduced HAE attack rate and improved
quality-of-life versus placebo in the phase 3 COMPACT trial.8,9
Although the comparative prophylactic effectiveness of C1-
INH(SC) and C1-INH(IV) is of clinical interest, head-to-head
data are not available. Thus, an exploratory analysis was per-
formed on a prespecified subgroup of COMPACT study par-
ticipants who were using C1-INH(IV) for routine prophylaxisbefore the study; prestudy HAE attack rates while using C1-
INH(IV) prophylaxis were compared with on-study attack
rates while using C1-INH(SC) prophylaxis.
Detailed methods and primary findings of the COMPACT
study have been reported elsewhere.8 Briefly, the study included
a screening period (up to 4 weeks) and a prophylaxis-free run-in
period (up to 8 weeks) during which attacks could be treated
with rescue HAE therapy, after which subjects were randomized
to crossover treatment with either C1-INH(SC) 40 or 60 IU/kg
administered twice weekly for 16 weeks, preceded or followed by
twice-weekly placebo for 16 weeks. The initial study protocol
allowed the use of C1-INH(IV) as prophylaxis within 3 months
before screening; this was later amended to preclude such pa-
tients because of institutional review board concerns over
potentially increased attack frequencies when C1-INH(IV) pro-
phylaxis was withdrawn. Eligible participants were individuals
12 years of age with type 1 or 2 HAE, with a history of 4
HAE attacks over any consecutive 2-month period before the use
of prophylactic therapy.
The subgroup for this analysis included 21 patients who entered
the COMPACT study after using C1-INH(IV) at variable doses
for routine prophylaxis of HAE attacks before screening; 13 pa-
tients previously used C1-INH(IV) prophylaxis at or above the
approved dose and/or frequency of 1000 IU every 3 to 4 days,3
whereas 8 patients were using regimens involving lower doses
and/or frequency than recommended (Table I). The mean (SD)
age was 46.3 (18.2) years, and 71% (n ¼ 15) were female. Attack
data while using C1-INH(IV) in the 3 months before screening
were obtained from patients’ medical charts. During the study,
investigators recorded attack information in electronic case report
forms based on patients’ daily electronic diaries (eDiaries). Patients
recorded anyHAE symptoms (regardless of the need for treatment)
in the eDiaries. Eight patients were randomized to a C1-INH(SC)
40 IU/kg sequence and 13 patients were randomized to a C1-
INH(SC) 60 IU/kg sequence.
The mean (standard deviation) time-normalized number of
HAE attacks (HAE attack rate per month) was determined
before screening and during study treatment. The HAE attack
rate per month per subject was calculated by dividing the total
number of HAE attacks during the period of interest by the
number of days of the period, and then multiplying the resulting
number of attacks per day by 30.4375 to yield the number of
attacks per month. The percentage reduction in monthly HAE
attack rate for C1-INH(SC) versus C1-INH(IV) was calculated
as follows: 100  (1 e [time-normalized number of HAE attacks
during treatment with C1-INH(SC)/time-normalized number of
HAE attacks prestudy]).
The time-normalized number of HAE attacks (primary
endpoint in the COMPACT study) was lower during the on-
study use of C1-INH(SC) prophylaxis than during the pre-
study use of C1-INH(IV) prophylaxis (mean, 1.2 vs 2.7 attacks/
month; median, 0.6 vs 2.0 attacks/month) (Table II). There was
a 52.1% mean reduction (73.6% median reduction) in HAE
attack rate from the prestudy use of C1-INH(IV) for routine
prophylaxis to the on-study use of C1-INH(SC) for routine
prevention. Findings were similar for the 40 and 60 IU/kg dose
groups individually.2035
TABLE I. Individual subject data
Prior C1-INH(IV)
prophylaxis by subject Prior C1-INH(IV) dose C1-INH(SC) dose (IU/kg)
Time-normalized number of HAE attacks (number/mo)
Prestudy C1-INH(SC)40 or 60 IU/kg BIW
Cinryze
1 1000 IU BIW 40 3.67 1.74
2 1500 IU Q3D 40 11.00 1.45
3 1000 IU BIW 40 3.00 1.16
4 1000 IU BIW 40 2.00 0.00
5 500 IU TIW* 40 1.33 0.29
6 1000 IU BIW 40 0.00 0.00
7 1000 IU BIW 60 1.67 0.00
8 1500 IU BIW 60 1.33 0.00
9 1000 IU QW* 60 1.67 1.15
10 1500 IU Q3D 60 1.33 0.60
11 1000 IU QW* 60 1.67 0.70
12 500 IU BIW* 60 2.00 0.62
13 1000 IU BIW 60 8.00 0.29
14 1000 IU BIW 60 1.67 e
15 1000 IU BIW 60 2.00 0.00
Berinert
16 1000 IU Q5D* 40 0.00 6.09
17 2000 IU BIW 40 2.33 4.35
18 1000 IU Q4D 60 0.67 1.48
19 2000 IU QW* 60 4.67 0.61
20 500 IU BIW* 60 3.00 0.64
Not specified
21 1000 IU QW* 40 2.67 2.90
Total
Mean (SD) 2.65 (2.57) 1.20 (1.58)
Min, Max 0.00, 11.00 0.00, 6.09
Median 2.00 0.63
BIW, Twice weekly; C1-INH(IV), intravenous human C1-inhibitor; C1-INH(SC), subcutaneous human C1-inhibitor; HAE, hereditary angioedema; Q3D/Q4D/Q5D, every 3/4/5
d; QW, once weekly; SD, standard deviation; TIW, 3 times weekly.
*C1-INH(IV) use at doses lower and/or less frequent than recommended (1000 IU every 3-4 d).
TABLE II. Monthly HAE attack rate by study phase and percentage reduction in attack rate
Study phase








Mean  SD (95% CI) 2.7  2.6 (1.5, 3.8) 2.9  3.5 (0.02, 5.9) 2.6  2.0 (1.3, 3.8)
Median (lower, upper quartile) 2.0 (1.3, 3.0) 2.2 (0.7, 3.3) 1.8 (1.5, 2.8)
C1-INH(SC)*
Mean  SD (95% CI) 1.2  1.6 (0.5, 1.9) 1.9  2.2 (0.04, 3.7) 0.7  0.8 (0.2, 1.3)
Median (lower, upper quartile) 0.6 (0.1, 1.5) 1.3 (0.1, 3.0) 0.6 (0.1, 0.9)
Percentage reduction in attack rate,
C1-INH(SC) on study vs C1-INH (IV) prestudy
Mean  SD (95% CI) 52.1  63.6 (20.4, 83.7) 48.8  68.4 (23.0, 120.5) 53.7  64.2 (12.9, 94.6)
Median (lower, upper quartile) 73.6 (52.6, 96.4) 69.8 (52.6, 86.8) 73.8 (43.2, 98.2)
C1-INH(IV), intravenous human C1-inhibitor; C1-INH(SC), subcutaneous human C1-inhibitor; CI, confidence interval; HAE, hereditary angioedema; SD, standard deviation.
*N ¼ 20 while using C1-INH(SC); 1 subject in the Placebo/ C1-INH(SC) sequence discontinued before the C1-INH(SC) period.
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2036 CLINICAL COMMUNICATIONSIn the absence of prospective head-to-head comparisons of
C1-INH(IV) and C1-INH(SC), this post hoc analysis of
COMPACT data provides the first evidence of the relative
effectiveness of C1-INH(SC) compared with the recent use of
C1-INH(IV). These findings suggest that patients onC1-INH(IV) prophylaxis may experience a clinically meaningful
reduction of HAE attacks after switching to C1-INH(SC). On
average, attack rates during the C1-INH(SC) use were reduced
by about half compared with prestudy C1-INH(IV) prophylaxis;
the median reduction of attacks per month was almost 74%.
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CLINICAL COMMUNICATIONS 2037This analysis has several limitations including a small sample
size and some dosing disparities. However, the previous use of
C1-INH(IV) reflected real-world, nonstandardized dosing that
varied greatly and in some cases was below approved dosing
recommendations (Table I).3 Although it could be assumed that
prestudy, real-world treatment was individualized for optimum
efficacy because C1-INH(IV) prescribing recommendations
allow for doses up to 2500 IU twice weekly,3 there was no way to
confirm such dose/administration frequency optimization for
each patient. In this analysis, more than one-third of patients
(n ¼ 8) used C1-INH(SC) at a dose of 40 IU/kg during the
COMPACT study, which is lower than the approved dose of 60
IU/kg7; thus the true treatment difference after switching to
approved dosing with C1-INH(SC) (60 IU/kg) may be under-
estimated by these data. Another limitation is the possibility of
patient selection bias, in that patients well controlled on
C1-INH(IV) prophylaxis may have been less likely to enroll in
the COMPACT study. Finally, the methodology for identifying
HAE attacks during the prestudy period was not systematic but
based on medical chart entries and patients’ histories, thus, not as
methodical as the systematic recording of attacks during the
COMPACT study treatment phases.
In summary, within the limitations of this subgroup analysis,
we conclude that patients previously using C1-INH(IV) at
various doses as routine prophylaxis can experience a substantial
and clinically meaningful reduction in HAE attack rate when
switching to C1-INH(SC). Additional clinical experience and
further studies will be needed to confirm these observations.Acknowledgments
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